(0.05%) 5 157.50 points
(0.07%) 38 861 points
(-0.04%) 17 994 points
(0.38%) $78.41
(0.56%) $2.15
(0.40%) $2 317.80
(1.87%) $27.19
(-0.21%) $963.25
(0.02%) $0.929
(-0.13%) $10.86
(0.00%) $0.797
(0.05%) $91.50
4 days till quarter result
(bmo 2024-05-10)
Expected move: +/- 10.23%
@ $5.43
Utstedt: 9 feb 2024 @ 21:55
Avkastning: -52.12%
Forrige signal: feb 7 - 20:00
Forrige signal:
Avkastning: 5.44 %
Live Chart Being Loaded With Signals
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases...
Stats | |
---|---|
Dagens volum | 45 783.00 |
Gjennomsnittsvolum | 91 236.00 |
Markedsverdi | 5.27M |
EPS | $0 ( 2024-04-01 ) |
Neste inntjeningsdato | ( $-2.18 ) 2024-05-10 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.0500 |
ATR14 | $0.0690 (2.65%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Sapirstein James | Sell | 174 | Common Stock |
2024-04-01 | Romano Sarah | Sell | 75 | Common Stock |
2024-03-15 | Sapirstein James | Sell | 1 887 | Common Stock |
2024-03-15 | Romano Sarah | Sell | 1 120 | Common Stock |
2024-03-13 | Syage Jack | Buy | 15 400 | Common Stock, par value $0.0001 per share |
INSIDER POWER |
---|
93.58 |
Last 95 transactions |
Buy: 5 900 618 | Sell: 1 318 677 |
First Wave BioPharma, Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
PDSB | 0.826 |
ALLK | 0.815 |
VCSA | 0.815 |
NAKD | 0.811 |
WTBA | 0.81 |
FREE | 0.809 |
LBPS | 0.804 |
LYRA | 0.804 |
TRIT | 0.803 |
CRBU | 0.801 |
10 Mest negative korrelasjoner | |
---|---|
BBIO | -0.836 |
NVDA | -0.834 |
LSCC | -0.834 |
ACVA | -0.828 |
PDFS | -0.827 |
BRKS | -0.823 |
OSW | -0.822 |
FTNT | -0.821 |
ADI | -0.821 |
RRGB | -0.82 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
First Wave BioPharma, Økonomi
Annual | 2023 |
Omsetning: | $0 |
Bruttogevinst: | $-29 274.00 (0.00 %) |
EPS: | $-46.96 |
FY | 2023 |
Omsetning: | $0 |
Bruttogevinst: | $-29 274.00 (0.00 %) |
EPS: | $-46.96 |
FY | 2022 |
Omsetning: | $0 |
Bruttogevinst: | $-106 207 (0.00 %) |
EPS: | $-461.72 |
FY | 2021 |
Omsetning: | $0.00 |
Bruttogevinst: | $0.00 (0.00 %) |
EPS: | $-1 377.25 |
Financial Reports:
No articles found.
First Wave BioPharma,
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties; and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.